Aniluxx Biotechnology

Aniluxx Biotechnology is dedicated to developing safe and effective treatments for pets, with a particular focus on therapeutic areas such as atopic dermatitis and osteoarthritis. The company has developed ALX 101, an investigational topical therapy for canine allergic dermatitis. Aniluxx Biotechnology participated in MassChallenge Houston and has presented at the North Carolina Biotechnology Center Symposium on Itch as well as the North Carolina Center for Entrepreneurial Development Life Sciences Conference. The company has filed an SEC Form D reporting seed stage investment.

Aniluxx Biotechnology applies advances in vehicle science to develop novel mechanisms for delivering topical applications, utilizing a technology called Paucimicron Emulsion for the simultaneous deposition of active ingredients and excipients on the skin surface. The company is committed to bringing biotech ingenuity to veterinary medicine and aims to transform the way pet diseases are treated by leveraging scientific advances in human health. Their portfolio includes product candidates for the treatment of atopic dermatitis, osteoarthritis, and other indications.

Aniluxx Biotechnology partners with leading academic institutions and other companies to advance science for pet health. The company is committed to identifying unmet needs of pet patients living with chronic conditions and developing novel therapies to address these needs.